Evidence map›Paper›PMID 30167848›Full record

ArticleHuman genetics2018

Rare coding variant analysis in a large cohort of Ashkenazi Jewish families with inflammatory bowel disease.

E R Schiff, M Frampton, N Ben-Yosef, B E Avila, F Semplici, N Pontikos, S L Bloom, S A McCartney, R Vega, L B Lovat and 9 more

Open access · hybridAbstract read
In one paragraph

Article in Human genetics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 8 institutions in 3 countries.

E R SchiffCentre for Molecular Medicine, Division of Medicine, University College London, London, UK.
M FramptonCentre for Molecular Medicine, Division of Medicine, University College London, London, UK.
N Ben-YosefCentre for Molecular Medicine, Division of Medicine, University College London, London, UK.
B E AvilaMedical and Population Genetics, Broad Institute, Cambridge, MA, USA.
F SempliciCentre for Molecular Medicine, Division of Medicine, University College London, London, UK.
N PontikosUCL Genetics Institute, Division of Biosciences, University College London, London, UK.
S L BloomDepartment of Gastroenterology, University College London Hospital, London, UK.
S A McCartneyDepartment of Gastroenterology, University College London Hospital, London, UK.
R VegaDepartment of Gastroenterology, University College London Hospital, London, UK.
L B LovatResearch Department of Tissue and Energy, Division of Surgery and Interventional Science, University College London, London, UK.
E WoodGastroenterology Department, Homerton University Hospital, London, UK.
A HartGastroenterology Department, St Mark's Hospital, London, UK.
E IsraeliInflammatory Bowel Disease Unit, Institute of Gastroenterology and Liver Diseases, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
D CrespiCentre for Paediatric Gastroenterology, Royal Free Hospital, London, UK.
M A FurmanCentre for Paediatric Gastroenterology, Royal Free Hospital, London, UK.
S MannGastroenterology Department, Barnet General Hospital, London, UK.
C D MurrayCentre for Gastroenterology, Royal Free Hospital, London, UK.
A W SegalCentre for Molecular Medicine, Division of Medicine, University College London, London, UK.
A P LevineCentre for Molecular Medicine, Division of Medicine, University College London, London, UK. a.levine@ucl.ac.uk.
University College London · GBThe Royal Free Hospital · GBBarnet Hospital · GBHadassah Medical Center · ILHomerton University Hospital · GBMassachusetts General Hospital · USSt Mark's Hospital · GBUniversity College Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rare variants are thought to contribute to the genetics of inflammatory bowel disease (IBD), which is more common amongst the Ashkenazi Jewish (AJ) population. A family-based approach using exome sequencing of AJ individuals with IBD was employed with a view to identify novel rare genetic variants for this disease. Exome sequencing was performed on 960 Jewish individuals including 513 from 199 multiplex families with up to eight cases. Rare, damaging variants in loci prioritized by linkage analysis and those shared by multiple affected individuals within the same family were identified. Independent evidence of association of each variant with disease was assessed. A number of candidate variants were identified, including in genes involved in the immune system. The ability to achieve statistical significance in independent case/control replication data was limited by power and was only achieved for variants in the well-established Crohn's disease gene, NOD2. This work demonstrates the challenges of identifying disease-associated rare damaging variants from exome data, even amongst a favorable cohort of familial cases from a genetic isolate. Further research of the prioritized rare candidate variants is required to confirm their association with the disease.

Indexed as

Genetic Predisposition to DiseaseGenetic VariationOpen Reading FramesCase-Control StudiesFemaleGenetic LinkageHumansInflammatory Bowel DiseasesJewsMaleNod2 Signaling Adaptor ProteinPedigreeSequence Analysis, DNANOD2 protein, humanNod2 Signaling Adaptor Protein

Identifiers

PMID30167848
PMCPMC6153494
OpenAlexW2888363938

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.